AI TRENDS | Ascletis Starts U.S. Phase I Study Of ASC36 For Obesity

Ascletis Pharma (01672) said it has started a U.S. Phase I study of ASC36 oral tablets for obesity after recently receiving U.S. Food and Drug Administration approval for an investigational new drug application, according to ETNet. The company said the Phase I study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending oral doses in 86 obese or overweight participants. ASC36 is an amylin receptor agonist peptide developed in-house using Ascletis' proprietary structure-based AI-assisted drug discovery technology.